Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 28.044
- Book/Share 21.5883
- PB 5.7735
- Debt/Equity 0.7773
- CurrentRatio 0.8179
- ROIC 0.1849
- MktCap 240887492759.0
- FreeCF/Share 8.6273
- PFCF 14.3334
- PE 25.2052
- Debt/Assets 0.3126
- DivYield 0.0321
- ROE 0.2294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Florent Cespedes - Bernstein Peter Verdult - BNP Paribas Exane Richard Vosser - JPMorgan James Quigley - Goldman Sachs Thibault Boutherin - Morgan Stanley Matthew Weston - UBS Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Steve Scala - TD Securities Operator Good morning and good afternoon, and welcome …
Read More
Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well
Published: April 29, 2025 by: CNBC Television
Sentiment: Positive
Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results.
Read More
Pharma firms maastraz
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Read More
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance.
Read More
Novartis Lifts Guidance After Profit, Sales Top Views
Published: April 29, 2025 by: WSJ
Sentiment: Positive
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.
Read More
Novartis more upbeat on 2025 guidance after strong Q1 momentum
Published: April 29, 2025 by: Reuters
Sentiment: Positive
Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.
Read More
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Published: April 26, 2025 by: The Motley Fool
Sentiment: Negative
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days.
Read More
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
Read More
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats
Published: April 10, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Read More
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Published: April 02, 2025 by: PRNewsWire
Sentiment: Neutral
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P
Read More
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P
Read More
Novartis (NVS) Could Be a Great Choice
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Published: March 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival ( rPFS) vs.
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
5 Large Drug Stocks to Watch as Industry Recovers
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Industry Description
Read More
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Read More
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Read More
Novartis Reports Updated Positive Data From Phase III SMA Program
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883